Otmar Pfister
Overview
Explore the profile of Otmar Pfister including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
1464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lauder L, Pfister O, Mahfoud F
Eur J Heart Fail
. 2024 Nov;
27(1):69-71.
PMID: 39513321
No abstract available.
2.
Hennings E, Aeschbacher S, Coslovsky M, Paladini R, Voellmin G, Lampart M, et al.
Clin Res Cardiol
. 2024 Sep;
114(2):239-250.
PMID: 39297942
Background And Aims: The role of biomarkers in diagnosing pulmonary hypertension (PH) and distinguishing between pre- and post-capillary PH remains poorly understood. We aimed to identify biomarkers with a strong...
3.
Greene S, Bohm M, Bozkurt B, Butler J, Cleland J, Coats A, et al.
J Card Fail
. 2024 Sep;
PMID: 39277029
Background: Despite guideline recommendations, many patients with heart failure (HF) do not receive target dosages of renin-angiotensin-aldosterone system inhibitors (RAASis) in clinical practice due, in part, to concerns about hyperkalemia...
4.
Monogiou Belik D, Bernasconi R, Xu L, Della Verde G, Lorenz V, Gruterich V, et al.
Apoptosis
. 2023 Nov;
29(3-4):357-371.
PMID: 37945814
Background: Tyrosine kinase inhibitors (TKIs) targeting fms-like tyrosine kinase 3 (Flt3) such as quizartinib were specifically designed for acute myeloid leukemia treatment, but also multi-targeting TKIs applied to solid tumor...
5.
Wussler D, Belkin M, Maeder M, Walter J, Shrestha S, Kupska K, et al.
Eur J Heart Fail
. 2023 Oct;
25(12):2218-2229.
PMID: 37871997
Aims: Sex-specific differences in acute heart failure (AHF) are both relevant and underappreciated. Therefore, it is crucial to evaluate the risk/benefit ratio and the implementation of novel AHF therapies in...
6.
Serban T, du Fay de Lavallaz J, Mannhart D, Pfister O, van der Stouwe J, Kaufmann B, et al.
ESC Heart Fail
. 2023 May;
10(4):2386-2394.
PMID: 37218391
Aims: Tachycardia-induced cardiomyopathy (TCM) represents a partially reversible type of cardiomyopathy (CM) that is often underdiagnosed and cardiac chamber remodelling in TCM remains incompletely understood. We aim to explore differences...
7.
Hennings E, Blum S, Aeschbacher S, Coslovsky M, Knecht S, Eken C, et al.
J Am Heart Assoc
. 2023 Mar;
12(6):e028255.
PMID: 36926939
Background Patients with atrial fibrillation (AF) face an increased risk of death and major adverse cardiovascular events (MACE). We aimed to assess the predictive value of the novel atrial-specific biomarker...
8.
Haegele M, Liu Y, Frey S, Strebel I, Jordan F, Wick R, et al.
J Cardiopulm Rehabil Prev
. 2023 Mar;
43(4):245-252.
PMID: 36912806
Purpose: The objective of this study was to quantify secondary prevention care by creating a secondary prevention benchmark (2PBM) score for patients undergoing ambulatory cardiac rehabilitation (CR) after acute coronary...
9.
Haegele M, Djurdjevic A, Jordan F, Liu Y, Mildner L, Frey S, et al.
J Clin Med
. 2022 Dec;
11(23).
PMID: 36498631
In 2019 the European Society of Cardiology (ESC) lowered the target values for low-density lipoprotein cholesterol (LDL-C) from <1.8 mmol/L to <1.4 mmol/L for secondary prevention of cardiovascular disease (CVD)....
10.
Schobi D, Zhang Y, Kehl J, Aissani M, Pfister O, Strahm M, et al.
J Am Heart Assoc
. 2022 Oct;
11(21):e027023.
PMID: 36314494
Background Acute heart failure is the most frequent cause of unplanned hospital admission in elderly patients. Various biomarkers have been evaluated to better assess the status of these patients and...